CN Patent

CN117580572A — 用安森司坦和帕博西尼治疗乳腺癌

Assigned to Sanofi Aventis France · Expires 2024-02-20 · 2y expired

What this patent protects

本公开文本提供了用安森司坦和帕博西尼的组合治疗乳腺癌的方法。

USPTO Abstract

本公开文本提供了用安森司坦和帕博西尼的组合治疗乳腺癌的方法。

Drugs covered by this patent

osimertinib-mesylate (OSIMERTINIB MESYLATE)

Patent Metadata

Patent number: CN117580572A
Jurisdiction: CN
Classification: —
Expires: 2024-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Aventis France
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.